| Rena Ali, | |
|
7272 W Marginal Way S, Seattle, WA 98108-4140 | |
| (206) 735-1451 | |
| Not Available |
| Full Name | Rena Ali |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 7272 W Marginal Way S, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215558119 | NPI | - | NPPES |
| 61051593 | Other | WA | DEPARTMENT OF HEALTH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 61051593 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rena Ali, 10 Prestwick Dr, Voorhees, NJ 08043-1433 Ph: (856) 426-3201 | Rena Ali, 7272 W Marginal Way S, Seattle, WA 98108-4140 Ph: (206) 735-1451 |
News Archive
A "danger molecule" is higher in the blood of younger black adults than whites, females than males and increases with weight and age, researchers report in the first large, longitudinal study associating circulating HMGB1 levels with obesity, inflammation promoters and early indicators of cardiovascular risk in humans.
Medicaid Health Plans of America, the leading trade association solely focused on representing Medicaid health plans, responded today to an annual report just released by the Centers for Medicare and Medicaid Services on Medicaid managed care enrollment, which showed Medicaid health plan enrollment grew by almost 2.4 million members in 2009 to more than 23.4 million Americans nationwide.
By increasing the level of a specific microRNA (miRNA) molecule, researchers have for the first time restored chemotherapy sensitivity in vitro to a line of human pancreatic cancer cells that had developed resistance to a common treatment drug.
Life Technologies Corporation today announced a series of new product innovations across the company's DNA sequencing portfolio. To date, most sequencing technologies have primarily addressed the needs of researchers in the highest throughput laboratories, limiting widespread accessibility of these powerful next-generation sequencing technologies.
Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors.
› Verified 2 days ago
Amy L Donaldson, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Autism Ctr, Box 357920, Seattle, WA 98195 Phone: 206-897-1801 | |
Ms. Carol L Ray, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4507 Sunnyside Ave N, Unit D, Seattle, WA 98103 Phone: 206-849-3937 | |
Ms. Linda E Eblen, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4800 Sand Point Way Ne, Mail Stop W-6839, Seattle, WA 98105 Phone: 206-987-6164 | |
Mrs. Genevieve Houdet-cote, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Ms:h4-pmr, Seattle, WA 98101 Phone: 206-341-0461 | |
Daelene King, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9100 5th Ave Ne, Seattle, WA 98115 Phone: 206-526-2662 | |
Molly Beier, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-744-3000 | |
Vassalo Speech And Language Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2300 W Bertona St, Seattle, WA 98199 Phone: 978-444-0321 |